// App-Quantinova.ai

BSH2020‐PO‐146 : One‐year efficacy and safety from a phase 3 trial of ravulizumab in adult patients with paroxysmal nocturnal hemoglobinuria receiving prior eculizumab treatment

Researchers

Presenter

  • A. Kulasekararaj

Principal Investigators

  • L. Mitchell

  • A. Hill

  • S. Langemeijer

  • R. Wells

  • F. A. Gonzlez Fernndez

  • A. Gaya

  • E. O. Gutirrez

  • C. Piatek

  • K. Usuki

  • A. Bosi

  • R. Brodsky

  • M. Ogawa

  • J. Yu

  • S. Ortiz

  • A. Rth

  • J. W. Lee

  • R. Peffault de la Tour

Medical Centers

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • University Hospital Monklands, North Lanarkshire

  • Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds,

  • Radboudumc, Nijmegen, Netherlands

  • Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

  • Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA

  • NTT Medical Center Tokyo, Tokyo, Japan

  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

  • Department of Surgery, Westgerman Cancer Center, University Hospital Essen, Essen, Germany

  • Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea,

  • Bone Marrow Transplantation Unit, Saint Louis Hospital, Assistance Publique–Hôpitaux de Paris

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint Louis Hospital and University Paris Diderot, Paris, France

Locations

  • United Kingdom

  • Netherlands

  • Canada

  • Spain

  • United States

  • Japan

  • Italy

  • Germany

  • France

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Cytoglobin

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • ALXN-1210

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03056040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved